EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 100 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $75,070 | -76.1% | 83,700 | -68.5% | 0.00% | – |
Q4 2022 | $313,620 | -77.1% | 265,780 | +45.9% | 0.00% | – |
Q3 2022 | $1,371,000 | +291.7% | 182,188 | +227.7% | 0.00% | – |
Q2 2022 | $350,000 | -32.0% | 55,600 | -10.3% | 0.00% | – |
Q1 2022 | $515,000 | -16.7% | 62,000 | -47.9% | 0.00% | – |
Q4 2021 | $618,000 | +19.5% | 119,109 | +54.1% | 0.00% | – |
Q3 2021 | $517,000 | +53.9% | 77,277 | +96.1% | 0.00% | – |
Q2 2021 | $336,000 | -96.0% | 39,400 | -95.8% | 0.00% | -100.0% |
Q1 2021 | $8,353,000 | -35.8% | 943,849 | -10.8% | 0.00% | -33.3% |
Q4 2020 | $13,009,000 | +64.1% | 1,058,502 | +8.7% | 0.00% | +50.0% |
Q3 2020 | $7,928,000 | -6.5% | 973,905 | +10.3% | 0.00% | -33.3% |
Q2 2020 | $8,480,000 | +46.2% | 883,300 | +3.5% | 0.00% | 0.0% |
Q1 2020 | $5,802,000 | -10.6% | 853,282 | +96.0% | 0.00% | 0.0% |
Q4 2019 | $6,487,000 | +47.2% | 435,353 | +1.3% | 0.00% | +50.0% |
Q3 2019 | $4,407,000 | +39.1% | 429,924 | +43.9% | 0.00% | +100.0% |
Q2 2019 | $3,168,000 | – | 298,828 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Telemetry Investments, L.L.C. | 135,848 | $2,024,000 | 6.74% |
INTERWEST VENTURE MANAGEMENT CO | 764,918 | $11,397,000 | 4.91% |
Knoll Capital Management, LLC | 350,238 | $5,219,000 | 3.85% |
683 Capital Management, LLC | 1,850,000 | $27,565,000 | 3.15% |
Soleus Capital Management, L.P. | 205,407 | $3,060,000 | 2.95% |
Broadfin Capital, LLC | 1,236,368 | $18,422,000 | 2.47% |
P.A.W. CAPITAL CORP | 144,000 | $2,146,000 | 2.29% |
MANGROVE PARTNERS IM, LLC | 847,284 | $12,625,000 | 1.85% |
Corriente Advisors, LLC | 203,898 | $3,038,000 | 1.63% |
Trellus Management Company, LLC | 63,850 | $951,000 | 1.59% |